Moreover, the targeting of METTL3 using nanoparticle-siRNA or METTL3-specific inhibitor (STM2457) synergized with anti-PD-1 treatment to reactivate CD8+ T cells and suppress the growth of orthoptic NAFLD-HCC tumors. Here, CD8A is linked to metabolic dysfunction-associated steatotic liver disease.